Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind active-controlled equivalence trial of nifuratel and nystatin vaginal soft capsules in vulvovaginal candidiasis
CTR20243128Phase 3Completed
- Sponsor
- Jiangsu Vanguard Pharmaceutical Co., Ltd.
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nifuratel + nystatin in vulvovaginal candidiasis (VVC), sponsored by Jiangsu Vanguard Pharmaceutical Co., Ltd.. Started Aug 2024; status: completed.
02
Drugs
nifuratel + nystatin
03
Conditions
vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on CTR20243128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243128.